Clinical efficacy and variations of T cell subsets in obese type 2 diabetes patients after metabolic surgery

摘要

To evaluate the clinical efficacy of metabolic surgery for obese type 2 diabetic patients based on a 2-year follow-up. To observe the variation of T cell subsets in obese type 2 diabetic patients after metabolic surgery. Methods: Eight obese type 2 diabetic patients underwent metabolic surgery and 8 non-obese type 2 diabetic patients treated with anti-diabetic medicine treatment were included in the surgery group and medicine group, respectively. Clinical and biochemical data were obtained from the subjects at each follow-up visit. Eight type 2 diabetic patients with obesity, who had undergone metabolic surgery, were included in the surgery group. Eight type 2 diabetic patients with obesity, who were treated with anti-diabetic medication, were included in the obesity medicine group. Additionally, 8 type 2 diabetic patients without obesity, who were treated with anti-diabetic medication, were included in the lean medicine group. Peripheral blood monocytes (PBMCs) and clinical and biochemical data were all obtained from the subjects at baseline and the 2nd month after treatment. The percentage of T-cell subsets was detected by flow cytometry. Conclusions: For type 2 diabetic patients with obesity, metabolic surgery is superior to anti-diabetic treatment on long-term blood glucose control. Two month after metabolic surgery, T cell subsets in type 2 diabetic patients with obesity had changed, along with weight loss and improvement in blood glucose.